- ISIN: CA87039X1096
- Land: Kanada
Alle Realtime Mitteilungen
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
29. November 07:30 Turnaround-Monday: XDAX macht 300 Punkte
29. November 07:37 Deutsche Telekom: Zu hohe Schulden – das ist die neue Strategie
29. November 07:44 Technologiekonzern vor wichtigem Termin: Platzt morgen der Knoten?
29. November 07:44 TSI Premium: Das System – alle Hintergründe
29. November 07:45 Trading-Tipp Zoom: Jetzt aber Gewinne mitnehmen
Original-Research: International School Augsburg -ISA- gemeinnützige AG (von GBC AG): GBC Vorstandsinterview
29. November 2021